← Home
💊 Pharmaceuticals — Top Stocks by Market Cap
1,859 companies · updated every 5–20 min
Pharmaceutical and biotech stocks on this page cover drug manufacturers and related healthcare innovators, ranked by market capitalisation. Large-cap pharma often mixes defensive cash-flow businesses with pipeline-driven growth names. Scan the sector leaders here, then open a company page for deeper market data.
We currently track 1,859 companies in Pharmaceuticals worldwide. Johnson & Johnson leads with a market cap of $639.74B, followed by AbbVie Inc. ($459.5B) and Roche Holding AG ($326.25B). Combined, the top 100 companies on this page are worth $5.61T.
| # | Name | Price | 24h % | 7d % | Market Cap | Volume (24h) | Last 7 Days |
|---|---|---|---|---|---|---|---|
| 1 |  Johnson & Johnson JNJ🇺🇸USD | $265.46 | -0.32% | +6.23% | $639.74B €554.08B | 143.36K shrs $38.06M | |
| 2 |  AbbVie Inc. ABBV🇺🇸USD | $260.03 | -0.65% | +6.94% | $459.5B €397.98B | 80.04K shrs $20.81M | |
| 3 | Fr 365.60 | -0.76% | +0.97% | Fr 291.3B $326.25B · €282.57B | 2.23K shrs Fr 816.02K | ||
| 4 | Fr 357.50 | -1.08% | +1.11% | Fr 284.84B $319.03B · €276.31B | 764.63K shrs Fr 273.35M | ||
| 5 |  Novartis AG NVS🇺🇸USD | $138.84 | -0.13% | +0.50% | $263.9B €228.56B | 85.86K shrs $11.92M | |
| 6 |  Novartis AG NOVN.SW🇨🇭CHF | Fr 114.12 | +0.18% | +1.28% | Fr 216.91B $242.94B · €210.41B | 1.91M shrs Fr 218.22M | |
| 7 |  AstraZeneca PLC AZN.L🇬🇧GBp | £1.20 | -1.15% | +1.94% | £186.32B $236.63B · €204.95B | 578.28K shrs £69.48M | |
| 8 |  Amgen Inc. AMGN🇺🇸USD | $380.23 | -0.33% | +4.13% | $205.56B €178.04B | 28.7K shrs $10.91M | |
| 9 | $144.89 | -0.48% | +0.74% | $179.66B €155.60B | 151.62K shrs $21.97M | ||
| 10 | $519.94 | +0.08% | +6.32% | $131.78B €114.14B | 10.22K shrs $5.31M | ||
| 11 | $64.09 | -0.01% | +1.64% | $130.93B €113.40B | 101.49K shrs $6.51M | ||
| 12 | €74.39 | -1.38% | -0.57% | €89.12B $97.15B | 493.57K shrs €36.72M | ||
| 13 | £0.18 | -0.30% | -1.40% | £74.06B $94.06B · €81.47B | 2.42M shrs £44.68M | ||
| 14 | $788.53 | -0.66% | +1.08% | $81.18B €70.31B | 14.19K shrs $11.19M | ||
| 15 | ¥6500.00 | +1.34% | -1.07% | ¥10.7T $71.66B · €62.07B | 1.91M shrs ¥12.4B | ||
| 16 | ¥5847.00 | +1.92% | +3.33% | ¥9.34T $62.55B · €54.18B | 4.67M shrs ¥27.28B | ||
| 17 | $988.48 | -0.21% | +6.57% | $61.47B €53.24B | 1.1K shrs $1.09M | ||
| 18 | $18.73 | +0.70% | +0.69% | $59.81B €51.81B | 108.89K shrs $2.04M | ||
| 19 |  Moderna, Inc. MRNA🇺🇸USD | $147.59 | +0.62% | +18.85% | $58.93B €51.04B | 307.72K shrs $45.42M | |
| 20 | €860.20 | -0.88% | -2.39% | €53.49B $58.31B | 8.53K shrs €7.34M | ||
| 21 | ₹1835.00 | -0.27% | -0.10% | ₹4.4T $52.83B · €45.76B | 1.44M shrs ₹2.64B | ||
| 22 | ₹1835.00 | -0.38% | — | ₹4.4T $52.83B · €45.76B | 42.15K shrs ₹77.35M | ||
| 23 | €48.64 | -1.40% | — | €47.79B $52.09B | 849.42K shrs €41.32M | ||
| 24 | ¥253.56 | -1.18% | +14.82% | ¥372.88B $51.46B · €44.57B | 1.48M shrs ¥375.34M | ||
| 25 | ₩1412000.00 | -0.56% | +1.52% | ₩65.36T $47.06B · €40.76B | 28.21K shrs ₩39.83B | ||
| 26 | $38.74 | +1.08% | +0.69% | $45.15B €39.10B | 87.95K shrs $3.41M | ||
| 27 | $207.00 | +0.92% | +10.62% | $44.37B €38.43B | 15.99K shrs $3.31M | ||
| 28 |  Haleon plc HLN🇺🇸USD | $9.23 | -1.70% | +5.03% | $40.59B €35.16B | 607.58K shrs $5.61M | |
| 29 | Fr 153.85 | -1.12% | +2.03% | Fr 35.88B $40.18B · €34.80B | 90.94K shrs Fr 13.99M | ||
| 30 | ¥11425.00 | +1.42% | +6.67% | ¥5.99T $40.16B · €34.78B | 1.05M shrs ¥11.95B | ||
| 31 | $353.55 | -0.08% | +5.29% | $39.99B €34.64B | 1.27K shrs $447.95K | ||
| 32 | HK$212.40 | -0.19% | +5.71% | HK$312.35B $39.98B · €34.63B | 2.27M shrs HK$481.23M | ||
| 33 | ¥43.13 | -0.05% | +9.80% | ¥286.26B $39.50B · €34.21B | 37.57M shrs ¥1.62B | ||
| 34 |  Haleon plc HLN.L🇬🇧GBp | £0.03 | -1.11% | +5.03% | £29.76B $37.80B · €32.74B | 9.85M shrs £33.32M | |
| 35 | ₪1.19 | +2.86% | +2.45% | ₪138.32B $37.35B · €32.35B | 614.63K shrs ₪72.96M | ||
| 36 | HK$43.80 | -2.67% | +5.28% | HK$290.71B $37.21B · €32.23B | 4.85M shrs HK$212.27M | ||
| 37 | ¥2836.50 | -0.32% | +4.53% | ¥5.16T $34.58B · €29.95B | 3.67M shrs ¥10.42B | ||
| 38 | $59.07 | +0.03% | +0.78% | $34.13B €29.56B | 62.64K shrs $3.7M | ||
| 39 | $247.43 | -1.03% | +4.68% | $33.11B €28.67B | 7.29K shrs $1.8M | ||
| 40 | Fr 66.00 | -0.75% | +1.73% | Fr 28.56B $31.98B · €27.70B | 232.75K shrs Fr 15.36M | ||
| 41 |  Biogen Inc. BIIB🇺🇸USD | $216.06 | -0.60% | +6.36% | $31.92B €27.65B | 6.78K shrs $1.47M | |
| 42 | $40.96 | -0.15% | +8.76% | $29.59B €25.62B | 56.58K shrs $2.32M | ||
| 43 | ₩177500.00 | -0.73% | +2.26% | ₩40.71T $29.31B · €25.38B | 226.82K shrs ₩40.26B | ||
| 44 | ₹9198.00 | -1.33% | -2.99% | ₹2.44T $29.30B · €25.38B | 380.79K shrs ₹3.5B | ||
| 45 | ₹9190.00 | -1.46% | -3.57% | ₹2.44T $29.28B · €25.36B | 15.27K shrs ₹140.3M | ||
| 46 | ¥2315.00 | +0.98% | -0.93% | ¥4.15T $27.81B · €24.09B | 4.66M shrs ¥10.79B | ||
| 47 | $124.83 | -0.38% | +4.75% | $27.26B €23.61B | 40.9K shrs $5.11M | ||
| 48 | HK$33.92 | -1.40% | +0.14% | HK$205.66B $26.32B · €22.80B | 8.72M shrs HK$295.77M | ||
| 49 | HK$49.22 | +0.16% | +12.56% | HK$202.59B $25.93B · €22.46B | 24.35M shrs HK$1.2B | ||
| 50 | $121.83 | -0.29% | +9.01% | $24.69B €21.39B | 33.39K shrs $4.07M | ||
| 51 |  BioNTech SE BNTX🇺🇸USD | $97.24 | -1.64% | +3.64% | $24.43B €21.16B | 31.53K shrs $3.07M | |
| 52 | ₹4850.00 | -2.33% | +2.81% | ₹1.84T $22.14B · €19.17B | 396.99K shrs ₹1.93B | ||
| 53 | $503.80 | +0.22% | +0.52% | $21.61B €18.71B | 6.44K shrs $3.25M | ||
| 54 | HK$95.00 | -1.91% | +5.64% | HK$165.67B $21.21B · €18.37B | 7.17M shrs HK$681.54M | ||
| 55 |  Genmab A/S GMAB🇺🇸USD | $32.49 | -0.47% | +6.55% | $19.98B €17.31B | 24.03K shrs $780.72K | |
| 56 | ₹4850.00 | -2.51% | — | ₹1.65T $19.74B · €17.10B | 6.24K shrs ₹30.25M | ||
| 57 |  Viatris Inc. VTRS🇺🇸USD | $16.65 | -0.06% | +2.73% | $19.12B €16.56B | 81.29K shrs $1.35M | |
| 58 |  Genmab A/S GMAB.CO🇩🇰DKK | kr 2105.00 | -0.52% | +5.36% | kr 129.44B $18.90B · €16.37B | 15.18K shrs kr 31.96M | |
| 59 | $263.20 | +6.17% | +12.24% | $17.26B €14.95B | 575.71K shrs $151.53M | ||
| 60 | NT$1345.00 | -4.27% | +24.20% | NT$556.45B $17.25B · €14.94B | 4.04M shrs NT$5.44B | ||
| 61 | ¥2918.50 | +2.26% | -1.35% | ¥2.48T $16.64B · €14.42B | 805.3K shrs ¥2.35B | ||
| 62 | $157.22 | +0.64% | +3.92% | $15.98B €13.84B | 778.67K shrs $122.42M | ||
| 63 | $245.87 | +0.03% | +3.15% | $15.96B €13.82B | 465.42K shrs $114.43M | ||
| 64 | kr 442.40 | -1.29% | +0.39% | kr 154.26B $14.96B · €12.96B | 51.04K shrs kr 22.58M | ||
| 65 | $18.42 | +4.96% | +0.91% | $14.69B €12.73B | 7.06M shrs $130.02M | ||
| 66 | HK$34.80 | +0.00% | -3.07% | HK$111B $14.21B · €12.31B | 5.4M shrs HK$187.78M | ||
| 67 | $72.38 | -0.08% | +8.58% | $14.15B €12.26B | 1.84M shrs $132.91M | ||
| 68 | HK$462.40 | -3.91% | +11.16% | HK$110.52B $14.15B · €12.25B | 697.46K shrs HK$322.51M | ||
| 69 | ¥246.88 | -2.03% | +26.73% | ¥101.93B $14.07B · €12.18B | 1.18M shrs ¥290.9M | ||
| 70 |  Exelixis, Inc. EXEL🇺🇸USD | $56.21 | +0.16% | +5.10% | $13.93B €12.06B | 1.67M shrs $93.9M | |
| 71 | ₹1361.00 | -0.29% | — | ₹1.1T $13.19B · €11.43B | 39.75K shrs ₹54.1M | ||
| 72 | ₹1099.00 | -1.83% | +2.26% | ₹1.1T $13.16B · €11.39B | 24.34K shrs ₹26.75M | ||
| 73 | ₹1099.00 | -1.80% | -0.27% | ₹1.1T $13.16B · €11.39B | 522.3K shrs ₹574.01M | ||
| 74 | ₹1351.00 | -1.10% | +1.65% | ₹1.09T $13.10B · €11.34B | 1.23M shrs ₹1.66B | ||
| 75 | ₩260000.00 | +0.00% | -5.38% | ₩18.09T $13.02B · €11.28B | 279.54K shrs ₩72.68B | ||
| 76 | $66.41 | +1.11% | +2.34% | $12.86B €11.13B | 1.34M shrs $88.73M | ||
| 77 | HK$8.70 | -1.86% | +1.75% | HK$99.23B $12.70B · €11.00B | 51.49M shrs HK$447.99M | ||
| 78 | ¥50.74 | -0.04% | -1.15% | ¥90.53B $12.49B · €10.82B | 4.86M shrs ¥246.69M | ||
| 79 | ₹1926.90 | -2.14% | +0.83% | ₹1.04T $12.49B · €10.82B | 1.54M shrs ₹2.96B | ||
| 80 | $540.06 | +1.04% | +0.19% | $12.48B €10.81B | 156.53K shrs $84.54M | ||
| 81 | ₹1923.00 | -2.40% | +4.00% | ₹1.04T $12.47B · €10.80B | 76.27K shrs ₹146.67M | ||
| 82 | HK$5.42 | -1.00% | -0.90% | HK$96.58B $12.36B · €10.71B | 59.15M shrs HK$320.6M | ||
| 83 | $107.94 | +0.69% | +10.61% | $12.25B €10.61B | 898.51K shrs $96.99M | ||
| 84 | €79.70 | +0.00% | +2.76% | €11.21B $12.22B | 31.76K shrs €2.53M | ||
| 85 | €79.40 | +0.00% | +2.32% | €11.18B $12.18B | 496 shrs €39.38K | ||
| 86 | €52.52 | +0.33% | — | €10.76B $11.73B | 162.54K shrs €8.54M | ||
| 87 | ₹1664.90 | -0.63% | — | ₹968.45B $11.62B · €10.07B | 8.25K shrs ₹13.73M | ||
| 88 | $23.15 | -0.09% | +3.93% | $11.56B €10.01B | 3.88M shrs $89.86M | ||
| 89 | ₹1149.75 | -0.97% | — | ₹957.25B $11.49B · €9.95B | 27.92K shrs ₹32.1M | ||
| 90 | ₹1660.00 | -1.18% | +1.20% | ₹955.13B $11.46B · €9.93B | 438.73K shrs ₹728.29M | ||
| 91 | ₹1145.00 | -1.76% | +2.97% | ₹953.77B $11.45B · €9.91B | 1.81M shrs ₹2.07B | ||
| 92 | $80.67 | -2.63% | +0.68% | $11.39B €9.87B | 1.32M shrs $106.42M | ||
| 93 | ¥26.75 | -0.63% | +0.77% | ¥82.21B $11.35B · €9.83B | 11.16M shrs ¥298.5M | ||
| 94 | $216.58 | -1.89% | -0.54% | $11.34B €9.83B | 718.46K shrs $155.6M | ||
| 95 | ₹2288.65 | +0.51% | -1.85% | ₹945.32B $11.34B · €9.82B | 9.46K shrs ₹21.65M | ||
| 96 | $72.27 | +0.21% | +26.20% | $11.33B €9.82B | 2.74M shrs $197.99M | ||
| 97 | ₹2063.20 | -1.52% | +1.68% | ₹943.43B $11.32B · €9.81B | 599.55K shrs ₹1.24B | ||
| 98 | ₹2280.50 | +0.02% | -1.51% | ₹941.95B $11.30B · €9.79B | 446.43K shrs ₹1.02B | ||
| 99 | ₹2055.35 | -1.94% | — | ₹939.23B $11.27B · €9.76B | 46.43K shrs ₹95.43M | ||
| 100 |  Akeso, Inc. 9926.HK🇭🇰HKD | HK$95.25 | -0.47% | +6.15% | HK$87.74B $11.23B · €9.73B | 8.54M shrs HK$813.54M |
Browse by Country
Europe
Asia